Under the first phase of the ongoing two part study, the drug demonstrated "statistically significant improvement in liver fibrosis and resolution of steatohepatitis compared to placebo." In August 2025, the company received final approval to market the therapy for the additional indication in the US, followed by a conditional approval in Canada in December
HealthHub combines provider-guided care, ongoing support, discreet delivery, and individualized treatment planning so that your experience reflects your goals, health history, and daily routine
Hope you're well
Simply taking them isn't enough taking them at the wrong time can reduce their effectiveness and leave you wondering why there's no visible result
- Mechanism: Enhances insulin secretion, suppresses glucagon, slows gastric emptying, promote satiety - Pharmacokinetics: Subcutaneous, ~1-week half-life, metabolized by proteolysis, excreted in urine/feces
Individual results vary, and your provider will set realistic expectations based on your starting point
